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ABSTRACT
The aim of toxicological screening is to de-
tect drugs of abuse and other drugs, or to 
demonstrate that they have not been taken. 
It is performed with a variety of tests capa-
ble to detect certain substance or a group 
of substances. Urine is a sample of choice 
for toxicological screening because of less 
invasive sampling and the prolonged de-
tection time of substances in urine. The 
Department of Laboratory Diagnostics 
at the University Hospital Centre Zagreb 
used to perform screening with thin-layer 
chromatography and confirm results with 
GC-MS analysis. Since September 2014, 
the Department has been using GC-MS 
for toxicological screening 24 hours a day. 
Compared to the previous period, the ex-
perience acquired so far has shown that 
there are a significantly lower number of 
samples with unknown substances that 
cannot be confirmed with certainty.
Key words: gas chromatography, mass spec-
trometry, toxicological screening
INTRODUCTION
The aim of toxicological screening is to 
detect drugs of abuse and other drugs, or 
to demonstrate that they have not been 
taken. In clinical toxicology, drug screen-
ing is performed when a patient exposed to 
drug shows signs of intoxication or over-
dose, with symptoms such as excitement, 
respiratory or central nervous system de-
pression or organ specific reactions: liver 
failure, cardiac arrhythmia or severe meta-
bolic acidosis.
In practice, it is not possible or necessary 
to test for all of the hundreds or thousands 
of clinical toxins that may be encountered. 
In reality, up to 24 drugs or agents account 
for 80% or more of intoxication cases 
treated in most emergency departments. 
(1, 2) The scope of clinical toxicology test-
ing provided by the laboratory will depend 
on the pattern of local drug use and on 
available resources of the institution, and it 
should be developed in consultation with 
the appropriate clinical staff. (2)
Laboratory testing for a single drug of 
abuse can help in antidote selection (N-
acetyl-cysteine for acetaminophen of na-
loxone for opiates). Drug toxicity is often 
recognizable based on history or clinical 
signs and symptoms, and treatment is 
general and supportive and therefore not 
influenced by drug screening results. Drug 
screening results are frequently not avail-
able soon enough to represent valuable 
information. However, clinical history is 
also not always available or reliable; symp-
toms are not clearly recognizable as drug 
or substance intoxication. Symptoms may 
be particularly confusing in case of multi-
ple drug intoxication. It is very important 
to rule in or rule out intoxication as a pos-
sible reason in patients with altered mental 
status or coma. (2)
 
Urine as a sample in toxicological screen-
ing
Urine is a sample of choice in emergency 
departments because of less invasive sam-
pling (unconscious patients demand cath-
eter use), as it is possible to obtain a large 
sample volume and the detection time 
of substances is usually a few days. Most 
drugs and drug metabolites are present in 
the urine in relatively high concentrations. 
For example, THC metabolites are lipo-
soluble and can be detected several days 
or even several weeks after consumption. 
(3) Detection times for some substances 
are shown in Table 1. The actual detection 
time depends on dose, frequency of use 
and individual metabolism. (4)
The patient’s degree of hydration has sig-
nificant influence on substance concentra-
tion in urine. Concentration of a substance 
in urine also depends on the amount of the 
substance used, on the volume of urine in 
the bladder, and later on the quantity of 
urine excreted.
METHODS AVAILABLE FOR TOXICO-
LOGICAL SCREENING
The proper selection of analytical meth-
ods requires knowledge of pharmacology 
and of pharmacokinetics of the substance 
of interest (for example, potential hepa-
totoxicity of acetaminophen is related to 
the concentration of unmetabolized drug; 
an analytical test should measure only the 
parent drug and not inactive metabolites).
Quantitative determination in serum is 
important only for some substances (for 
example acetaminophen, ethylene glycol, 
teophyline, digoxin); as regarding a large 
number of other drugs, their serum con-
centration and clinical picture do not cor-
relate. In these cases, qualitative identifica-
tion in urine is generally sufficient.
Screening methods are rapid, usually 
qualitative and they have adequate sensi-
tivity, but they are not highly specific. A 
negative result obtained by a screening test 
rules out the presence of clinically signifi-
cant concentrations of a particular analyte. 
Every positive result must be confirmed by 
a procedure of greater specificity. Screen-
ing procedures are designed to detect one 
drug or a group of drugs and involve the 
following:
- Simple visual colour tests (spot tests) 
which are qualitative and noninstrumen-
tal; every positive result must be confirmed 
with a more specific method.
- Serum osmol gap, which is the difference 
between the actual osmolality; measured 
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by freezing-point depression and the cal-
culated osmolality. When present in signif-
icant concentrations, alcohols, acetone and 
ethylene glycol increase serum osmolality 
for >10 mOsm/kg.
- Immunoassays can detect a single drug 
(e.g., cocaine, methadone) or a group of 
drugs (e.g., amphetamines, opiates). They 
are very simple to use, automated, semi-
quantitative and rapid with a low detec-
tion limit (0.02-1.0 µg/mL). The main 
disadvantage of immunoassays is that they 
provide false-positive results and require a 
second test for confirmation. (3 - 6)
- Chromatographic methods are able to 
detect a wide range of drugs and metabo-
lites (thin-layer chromatography-TLC, gas 
chromatography- GC; high performance 
liquid chromatography-HPLC). 
TLC is operationally relatively simple and 
inexpensive. After extraction and speci-
men spotting, the TLC plates are devel-
oped with appropriate solvents to achieve 
chromatographic resolution. Drugs and 
metabolites are then visualised as spots by 
their fluorescence or ultraviolet absorb-
ance and by their colour development with 
a combination of dip solutions. Identifica-
tion is made by co-chromatographing ref-
erence compounds with the unknown sub-
stances, followed by comparison of their 
relative migration distances (Rf values) 
and detection characteristics with those 
of the unknown substances. Identification 
requires considerable experience, skill and 
various detection colour hues.
HPLC is often used for toxicological 
screening. The advantage of HPLC over 
GC is the ability to analyse polar com-
pounds without derivatization (e.g., mor-
phine) and thermally labile drugs (e.g., 
chlordiazepoxide).
GC is relatively rapid and capable of re-
solving a broad spectrum of drugs and is 
widely used for qualitative and quantita-
tive drug analysis. Common detectors for 
drug detection by GC are flame ionisa-
tion detectors and mass spectrometers. 
GC is a chromatographic technique based 
on repeated partition and adsorption be-
tween the mobile phase and a stationary 
phase. The mobile phase is always gas. A 
sample must be introduced into the analy-
sis system in the form of vapour, which is 
achieved by heating the sample before it 
reaches the column. In GC-MS analysis, a 
substance eluted from the column reaches 
mass spectrometer where it is ionized and 
fragmented. After data processing, the re-
sult is mass spectrum; a graphic display of 
abundance in function of mass and charge. 
A mass spectrum of molecular fragments 
is characteristic of the molecule (similar to 
a finger print) and allows molecule iden-
tification by comparing created ions and 
their intensity with the spectrum of sub-
stances from the commercially available 
library. (7)
It is important to highlight that LC-MS 
(-MS) analysis is capable of analysing a 
much wider range of compounds (includ-
ing polar and thermally labile without 
derivatization) with shorter time analysis 
and greater selectivity and sensitivity. (8) 
Due to these above mentioned advantages, 
LC-MS-MS has certainly found a place in 
the analysis of new drugs such as synthetic 
cannabinoides.
CHANGES IN OUR LABORATORY
Until September 2014, immunoassays 
for targeted screening, TLC for general 
screening (24 hours a day) and GC-MS 
for confirmation in the event of a positive 
sample during regular working hours were 
used in our laboratory. Confirmations on 
GC-MS were conducted by an analytical 
toxicology specialist. In the spring of 2014, 
the manufacturer discontinued produc-
tion of TLC plates and the laboratory was 
in a situation to perform general screening 
only with immunoassays for methadone, 
cocaine, THC, benzodiazepines, ampheta-
mines, and opiates, and to rely on GC-
MS analysis only during regular working 
hours. The laboratory did not have enough 
analytical toxicology specialists to cover 
GC-MS screening 24 hours a day, and it 
was also financially unjustifiable. There 
were, however, a sufficient number of labo-
ratory medicine specialists who were will-
ing to learn how to handle GC-MS, so it 
was decided to try to introduce GC-MS 
screening into our laboratory for emer-
gency service needs. The main problem 
was how to create our internal database 
that would automatically notify the ana-
lyst which substance/s is/are present in the 
screened sample. Therefore, one colleague 
started hard-labouring and embarked on a 
long-term job: to create our internal data-
base. It was difficult work, as she physically 
screened every sample containing a known 
substance and then recorded its retention 
time and three or more mass ions that are 
characteristic for the substance. Today our 
internal database contains information on 
240 substances and is still growing. It is al-
ways possible that a substance of interest 
is not in the internal database, but labora-
tory medicine specialists also learned how 
to search commercially available libraries. 
Library searching is not always easy and 
requires a lot of experience to learn all 
the “tricks” (e.g., spectrum cleaning) to be 
100% sure of the substance found. A result 
of toxicological screening always says that 
the presence of a substance is suspected. If 
a clinician wants, they can ask for screen-
ing confirmation on the next working day.
GC-MS as a screening method has its own 
limitations:
- Thermolabile and polar compounds can 
not be screened (e.g., opiates must be deri-
vatized before GC-MS analysis)
- We cannot screen for substances that are 
not in the library (e.g., synthetic cannabi-
noides, new synthetic drugs…)
- Time-consuming (it lasts longer than 
TLC, approx. 1.5 hour from sample recep-
tion to results).
Because of the above mentioned first two 
limitations, it is always emphasised in the 
laboratory report that the analysis does not 
cover all psychoactive substances.
In drug screening, analysts do not rely only 
on GC-MS analysis for opiates, THC, ben-
zodiazepines and amphetamines. These 
substances can not always be seen on GC-
MS. Because analysts do not want to miss 
any substances, immunoassays for these 
are also performed.
From September 2014 to May 2015, a total 
of 233 toxicological screenings were per-
formed on GC-MS. In these samples, 55 
different substances were found. As shown 
in table 2, the most frequent among de-
tected drugs were: antipsyhotics (39 sam-
ples), anxiolytic sedative hypnotics - ben-
zodiazepines (32 samples), antidepressants 
(27 samples), antiepileptics (26 samples). 
Local anesthetic (lidocaine) was present 
in 53 samples due to urine sampling with 
catheter containing lidocaine. 
During the same period one year earlier 
(September 2013 - May 2014), 343 toxi-
cological screenings were performed with 
TLC and only 32 different substances 
were found. Some details of toxicological 
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screening results are shown in table 2. On 
TLC, analysts were not able to see which 
benzodiazepine, phenotiazine or tricyclic 
antidepressant was present in the sample; 
they were just able to see them as a group. 
On GC-MS, the exact substance can be 
seen, which is very important for benzo-
diazepines as the therapeutic range for this 
drugs very much varies from benzodiaz-
epine to benzodiazepine. This information 
can point to a toxic concentration of a cer-
tain benzodiazepine in a patient. 
It is important to point out that TLC 
screening detected 25.1% samples with 
unknown substances that are impossible 
to confirm with certainty, and only 2.6% of 
such samples were detected with GC-MS 
screening (mostly due to the fact that we 
did not have some of the substances in the 
internal database yet).
Only a few requests for screening confir-
mation were received since clinicians are 
provided with more information from GC-
MS screening than from TLC screening, 
especially when a sample contains several 
drugs. 
From September 2014 to May 2015, 436 
targeted screenings were performed: for 
benzodiazepines (59.9% were positive), 
147 for opiates (4.8% were positive), 53 for 
methadone (24.5% were positive), 54 for 
cocaine (1.9% were positive), 77 for am-
phetamines (8.5% were positive), and 150 
for THC (18.1% were positive).
Although the number of samples for gen-
eral toxicological screening decreased 
by 32%, the number of samples without 
any substance found still remained simi-
lar and relatively high (38.6%). The same 
phenomenon was observed for targeted 
screening. These data point at the impor-
tance of communication between clini-
cians and laboratory in order to reduce the 
number of unnecessary screening tests. It 
is also very important that the analyst re-
ceive information regarding symptoms, 
substances taken (if the clinician has that 
information from the patients themselves 
or from someone else) or substances ad-
ministered during emergency medical 
services. Such information can reduce the 
number of unnecessary general screenings 
and can direct targeted screening, which 
is both cheaper and faster. In case of, for 
example, synthetic cannabinoides, it can 
rule out screening because it is not possi-
ble to detect these substances with current 
equipment.
CONCLUSION
Although GC-MS analysis is time-con-
suming, more expensive and a demanding 
method, it provides clinicians with more 
information than TLC. The Department of 
Laboratory Diagnostics at the University 
Hospital Centre Zagreb demonstrated that 
GC-MS can be successfully used for toxi-
cological screening 24 hours a day. GC-MS 
screening significantly lowered the num-
ber of samples with unknown substances 
that are impossible to prove with certainty.
The Department of Laboratory Diagnos-
tics at the University Hospital Centre Za-
greb is the only laboratory in Croatia that 
performs toxicological screening 24 hours 
a day during the whole year on GC-MS. 
This method introduction was a very brave 
and demanding step. Currently there are 
15 specialists performing toxicological 
screenings. They continue to learn since 
every new toxicological case is material for 
discussion. It is very important to be aware 
of the limitations of the methods used for 
screening and to introduce them to clini-
cians. On the other hand, it is also very 
important for the laboratory to receive 
information regarding the patient status, 
symptoms, drugs a patient is taking or has 
received during emergency medical ser-
vices. This valuable information can guide 
toxicological analysis in the right direc-
tion.
Table 1. Detection time for some substances
SUBSTANCE DETECTION TIME UP TO
Amphetamine-Type Stimulans  
Amphetamine 3 days
Methamphetamine 3 days
 Methylenedioxyamphetamine (MDA) 2 days
Methylenedioxymetamphetamine (MDMA) 2 days
Benzodiazepines  
Long-acting (Diazepam, Nordiazepam) 10 days
Intermediate-acting (Alprazolam, Lorazepam, Oxazepam, Temazepam, 
Chlordiazepoxide, Clonazepam, Flunitrazepam)
5 days
Short-acting (Triazolam, Flurazepam) 2 days




Single use 3 days
Moderate use (4 times per week) 5 days
Heavy use (daily) 10 days
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Chronic heavy use 30 days








Table 2. Substance groups found in toxicology screening
SUBSTANCE GROUP September 2013-April 2014   
TOXICOLOGICAL  
SCREENING (TLC)










antihypertensive 2  
antiparkinsonic  2
antiplatelet drug  3
antipsyhotic 11 39
antitussic  2
anxiolytic and sedative hypnotic (benzodiaz-
epine)
40 32
barbiturate, anesthetic  1
beta blocker  18
bronchodylatator  6
diuretic  1
H2 blocker 1  
6-monoacethylmorphine (heroin metabolite)  1
hypnotic 1 6
illicit drug 9 4
local anesthetic 11 53
NSAID 2 17
analgesic, antitussic opiate 1 2
opiate analgesic  2
sinthetic opioid analgetic 19
synthetic opioid narcotic 7 7
tetracyclic antidepressant 13
tricyclic antidepressant 5  
GC-MS - gas chromatography - mass spectrometry, NSAID - nonsteroidal anti-inflammatory drug, TLC - thin layer chromatography
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Table 3. Some details of toxicological screening results
 September 2013-April 2014  
ŽTOXICOLOGICAL  
SCREENING (TLC)
September 2014-April 2015   
TOXICOLOGICAL  
SCREENING (GC-MS)
TOTAL NUMBER OF TOXICOLOGICAL 
SCREENING SAMPLES
343 233
NUMBER OF SAMPLES WITHOUT ANY 
SUBSTANCE
125 (36.4%) 90 (38.6%)
NUMBER OF SAMPLES WITH ONLY ONE 
SUBSTANCE
80 (23.3%) 15 (6.4%)
NUMBER OF SAMPLES WITH MORE THAN 
ONE SUBSTANCE 
52 (15.2%) 120 (51.5%)
NUMBER OF SAMPLES WITH UNKNOWN 
SUBSTANCE 
86 (25.1%) 6 (2.6%)
NUMBER OF SAMPLES WITHOUT ANALY-
SIS (SHORT SAMPLE VOLUME)
 2 (0.9%)
TOTAL NUMBER OF DIFFERENT SUB-
STANCES FOUND
32 55
GC-MS - gas chromatography - mass spectrometry
TLC - thin layer chromatography
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